Metabolic test with fluorine-18-fluorodeoxyglucose in staging and detection of residual tumor or recurrence in Hodgkin lymphoma

Clinics

Volumn 62, Issue 2, 2007, Pages 121-126

  Pracchia, Luís Fernando ^a   Chaves, Anna Alice Rolim ^a   Cerci, Juliano Julio ^a   Soares Jr , José ^a   Meneghetti, José Cláudio ^a   Buccheri, Valeria ^a  

^a NONE

Author keywords

Fluorodeoxyglucose (FDG); Hodgkin lymphoma; PET; Staging

Indexed keywords

EID: 34248353564     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322007000200005     Document Type: Article

References (15)

1. Brandt L, Kinby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in Hodgkińs disease. Acta Oncologica. 2001;40:185-97.
2. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin disease. J Clin Oncol. 1989;7:1630-6.
3. Castellino RA, Hoppe RT, Blank N. Computed tomography, lymphography and staging laparotomy: correlations in initial staging of Hodgkińs disease. Am J Radiol. 1984;143:37-41.
4. Munker R, Glass J, Griffeth LK, Sattar T, Zamani R, Heldmann M, et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol. 2004;15:1699-704.
5. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hanel A, Bredow J, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer. 2004;90:620-5.
6. Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, et al. Whole-body positron emission tomography using 18Ffluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol. 2002;81:20-5.
7. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica. 2001;86:266-73.
8. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol. 2000;11:1273-9.
9. Panizo C, Perez-Salazar M, Bendandi M, Rodriguez-Calvillo M, Boan JF, Garcia-Velloso MJ, et al. Positron emission tomography using 18Ffluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma. 2004;45:1829-33.
10. Guay C, Lepine M, Verreault J, Benard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med. 2003;44:1225-31.
11. Weihrauch MR, Re D, Scheidhauer K, Ansen S, Dietlein M, Bischoff S, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98:2930-4.
12. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Soderstrom KO, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995;86:3522-7.
13. Tatsumi M, Kitayama H, Sugahara H, Tokita N, Nakamura H, Kanakura Y, et al. Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med. 2001;42:601-8.
14. Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Wimmer G, Wahl G, et al. Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma - compared with conventional diagnostic methods. Nuklearmedizin. 2000;39:166-73.
15. Delbeke D, Martin WH, Patton JA, Sandler MP. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and x-ray based attenuation maps. Radiology. 2001;218:163-71.